openPR Logo
Press release

Global Glioblastoma Multiforme Treatment (GBM) Market Finds Lucrative Prospects In Asia Pacific, Global Market To Exhibit 11.40% CAGR

06-28-2017 02:54 PM CET | Health & Medicine

Press release from: Transparency Market Research

Global Glioblastoma Multiforme Treatment (GBM) Market Finds

Glioblastoma multiforme (GBM) is the most frequent and lethal primary brain tumor in adults. The current treatment modalities available in the market are surgical resection followed by chemotherapy and radiotherapy, that unable to increase the overall survival of patient. The main reason behind inability of these treatments are frequent recurrence, invasiveness of GBM and resistance of glioma stem cells to conventional treatments. Therefore, novel alternative treatment strategies are desperately needed and pipeline of GBM already involves a mix of biological, immunotherapy, small molecules and other types of therapeutics. Recent advancements in molecular biology and gene technology have provided attractive novel treatment possibilities for the patients diagnosed with GBM.

A new report published by Transparency Market Research on the global glioblastoma treatment market provides insights into the growth drivers, potential restraints, and growth opportunities that the market is likely to witness between 2014 and 2022. The report is titled “Glioblastoma Multiforme Treatment (GBM) Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022” and is available for sale in the company website. The market, according to the report, will grow from a valuation of US 0.34 bn in 2013 to US$0.91 bn in 2022, exhibiting a positive CAGR of 11.40% during the period.

Obtain Report Details @http://www.transparencymarketresearch.com/pipeline-review-of-glioblastoma-treatment-market.html

Novel treatment strategies are, therefore, desperately required to address such unmet medical needs, and the GBM pipeline already includes a mix of small molecules, immunotherapy, biological, and other types of therapeutics. Advances introduced in gene technology and molecular biology also provide lucrative novel possibilities for efficient treatment of patients diagnosed with GBM. The report discusses the aforementioned factors in detail as the most crucial growth drivers of the glioblastoma treatment market.

Some of the glioblastoma treatments approved by the FDA include bevacozumab, temozolomide, and carmustine. Of these, carmustine, known by the brand name Gliadel (a product of Arbor Pharmaceuticals, LLC), is surgical implant. Likewise, bevacozumab, brand named Avastin by Genetech/Roche, is used for intravenous therapy and temozolomide (brand named Temodal/Temodar/Temcad) is primarily recommended for oral or intravenous chemotherapy. The report analyzes the market dynamics of these available drugs and therapies. It also studies their effectiveness in glioblastoma treatment to measure the scope for novel therapies.

According to the report, rising awareness regarding the types of brain tumors, increased funding for R&D in drug delivery technologies, and the introduction of modern diagnostic techniques fuel the market for glioblastoma treatment. Among the available modalities, in 2013, the glioblastoma treatment market was dominated by temozolomide. However, the drug recently lost its patent, allowing generic drugs to foray into the market and significantly bring down the market share of temozolomide.

Among the regional markets for glioblastoma treatment, North America occupied the leading position due to the high incidence of glioblastoma multiforme in the region. The presence of an increasing number of associations, such as the National Brain Tumor Society, the American Brain Tumor Association, the Brain Tumor Foundation of Canada, and others, that are engaged in boosting the awareness regarding GBM across the region is aiding the growth of the North America glioblastoma treatment market.

Fill The Form To Gain Deeper Insights On This Market @ http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4807

Moreover, most prominent GBM drug manufacturers are located in the region, which further fuels the glioblastoma treatment market in North America. Asia Pacific, according to the report, will emerge as the most lucrative market for glioblastoma treatment drugs in the coming years. Rising awareness regarding GBM and rapid development of the healthcare infrastructure in several countries in Asia Pacific is propelling the glioblastoma treatment market in the region.

About Us
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Contact us:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Glioblastoma Multiforme Treatment (GBM) Market Finds Lucrative Prospects In Asia Pacific, Global Market To Exhibit 11.40% CAGR here

News-ID: 600305 • Views: 317

More Releases from Transparency Market Research

Wood Pellet Market- Industrial Forecast, Market Analysis and Trends 2023
Transparency Market Research, in a report titled "Wood Pellets Market -Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023," states that the estimation of the global wood pellets market is anticipated to ascend from US$6.2 bn in 2014 to US$20 bn in 2023. In the event that these qualities remain constant, the report expresses that the market will enroll a 14.10% CAGR in that. View exclusive Global strategic
Electrical Submersible Pumps Market is projected to reach US$16.75 bn by the end …
An enormous number of unmistakable undertakings with solid brands right now speak to the greater part in the global electrical submersible pumps (ESPs) market. This furnishes the market with a profoundly focused seller scene. As indicated by Transparency Market Research (TMR), the main four organizations working in the market, containing Schlumberger Limited, Borets Company, LLC, Baker Hughes Incorporated, and GE Oil and Gas, held over 86% of the worldwide ESP
Circulating Fluidized Bed Boilers Market 2023 - Opportunities And Challenges
Innovation varieties, the ongoing advances in plan, and divided assembling have brought about a high level of rivalry in the global circulating fluidized bed (CFB) boilers advertise. This thusly has constrained the main endeavors in the market, for example, Alfa Laval AB, AE&E Nanjing Boiler Co. Ltd., Bharat Heavy Electricals Limited (BHEL), and others to concentrate on direct advertising. According to Transparency Market Research (TMR), most of these organizations as
Power Transmission Towers and Cables Market 2023 : Forecasts, Technologies, Play …
The global power transmission towers and cables market features an exceptionally divided and a particularly unique working condition, discovers Transparency Market Research (TMR). A portion of the main merchants in the market are Kalpataru Power Transmission Ltd., Zhejiang Shengda Steel Tower Co., Ltd., Nanjing Daji Iron Tower Manufacturing Co. Ltd., ShanDong DingChang Tower Co., Ltd., KEC International, Ltd., and Sumitomo Electric Industries, Ltd. Countless players working in this divided landscape

All 5 Releases


More Releases for GBM

2019 - 2025 Glioblastoma Multiforme Treatment Market | GBM Market
Global Glioblastoma Multiforme Treatment Market, Its Market Trends And Analysis Glioblastoma multiforme is the high-grade glioma and potent malignant brain tumor that affects glial cells. Glioblastoma multiforme contains the complexly differentiated neoplastic astrocytes which are the subtype of central nervous system. Glioblastoma multiforme is different from the anaplastic astrocytoma due to the presence of hyperplastic blood vessels and necrotic tissue. Request Sample Report: https://precisionbusinessinsights.com/request-sample?product_id=16248 The global glioblastoma multiforme treatment market is
Glioblastoma Multiforme Treatment (GBM) Market Value to Reach US$0.91 bn 2022
Glioblastoma multiforme (GBM) is a high-grade gliomas and the most malignant astrocytic tumor, composed of complexly differentiated neoplastic astrocytes, a subtype of central nervous system (CNS). Glioblastoma is clinically classified as grade IV astrocytoma and differs from anaplastic astrocytoma (grade III) due to the presence of necrotic tissue and hyperplastic blood vessels. View Report- https://www.transparencymarketresearch.com/pipeline-review-of-glioblastoma-treatment-market.html The diagnosis of GBM is carried out with imaging modules such as computed tomography (CT), magnetic resonance
Glioblastoma Multiforme Treatment (GBM) Market is exhibiting a positive CAGR of …
Keen players in the global glioblastoma multiforme (GBM) treatment market are striving to maintain their foothold via novel product offerings. These players are focusing hard on the development of newer biological drugs with fewer side effects, which are usually associated with the consumption of immunosuppressants and chemotherapeutic agents. Collaborations with diagnostic laboratories in order to raise awareness regarding treatment options for glioblastoma multiforme is another key growth strategy adopted by market
Glioblastoma Multiforme (GBM) Global Clinical Trials Review, H2, 2016
Summary: ReportsWeb.com published “Glioblastoma Multiforme (GBM)” from its database. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Original Content: Publisher's clinical trial report, "Glioblastoma Multiforme (GBM) Global Clinical Trials Review, H2, 2016" provides an overview of Glioblastoma Multiforme (GBM) clinical trials scenario. This report provides top line data relating to the clinical trials
Glioblastoma Multiforme Treatment (GBM) Industry Analysis by Segments
Glioblastoma multiforme (GBM) is a high-grade gliomas and the most malignant astrocytic tumor, composed of complexly differentiated neoplastic astrocytes, a subtype of central nervous system (CNS). Glioblastoma is clinically classified as grade IV astrocytoma and differs from anaplastic astrocytoma (grade III) due to the presence of necrotic tissue and hyperplastic blood vessels. The diagnosis of GBM is carried out with imaging modules such as computed tomography (CT), magnetic resonance imaging
Glioblastoma Multiforme Treatment (GBM) Market Will Increase Strongly Through 20 …
Glioblastoma multiforme (GBM) is a high-grade gliomas and the most malignant astrocytic tumor, composed of complexly differentiated neoplastic astrocytes, a subtype of central nervous system (CNS). Glioblastoma is clinically classified as grade IV astrocytoma and differs from anaplastic astrocytoma (grade III) due to the presence of necrotic tissue and hyperplastic blood vessels. The diagnosis of GBM is carried out with imaging modules such as computed tomography (CT), magnetic resonance imaging